Abstract

Abbreviations EBV Epstein-Barr virus GO gene ontology GWAS genome-wide association analysis HBV hepatitis B virus HCV hepatitis C virus HLA human leukocyte antigen KEGG Kyoto encyclopedia of genes and genomes LD linkage disequilibrium NPC nasopharyngeal carcinoma PIP posterior inclusion probability QC quality control TWAS transcriptome-wide association analysis ZEBRA BamHI Z EBV replication activator Dear Editor, Nasopharyngeal carcinoma (NPC) is a common malignancy in East and Southeast Asia, especially in South China. [...]using the cis-regulated expression in addition to genetic variants to explore NPC susceptibility genes could be promising and reasonable for mechanistic and functional inference. Herein, we integrated genome and transcriptome data of 89 nasopharyngeal tumor tissues and investigated the associations between predicted gene expression levels and NPC risk using multicenter GWAS data involving 4506 NPC cases and 5384 cancer-free subjects (defined as controls) from South China. HLA-DOB may impact viral clearance capacity and persistent infection of hepatitis B virus (HBV) and hepatitis C virus (HCV) [ 9]. Since EBV reactivation with elevated EBV DNA load or antibodies was observed at the preclinical phase of NPC, we hypothesized that HLA class II genes, especially HLA-DQB1and HLA-DOB, participate in the early stage of NPC tumorigenesis by influencing EBV infection.

Details

Title
Transcriptome‐wide association analysis identified candidate susceptibility genes for nasopharyngeal carcinoma
Author
Yong‐Qiao He 1 ; Wen‐Qiong Xue 1 ; Dan‐Hua Li 1 ; Tong‐Min Wang 1 ; Zhi‐Ming Mai 2 ; Da‐Wei Yang 3 ; Chang‐Mi Deng 1 ; Liao, Ying 1 ; Wen‐Li Zhang 1 ; Ruo‐Wen Xiao 1 ; Luo, Luting 3 ; Diao, Hua 3 ; Tong, Xiating 3 ; Wu, Yanxia 1 ; Jiang‐Bo Zhang 1 ; Zhou, Ting 1   VIAFID ORCID Logo  ; Xi‐Zhao Li 1 ; Pei‐Fen Zhang 1 ; Xiao‐Hui Zheng 1 ; Shao‐Dan Zhang 1 ; Ye‐Zhu Hu 1 ; Tang, Minzhong 4 ; Zheng, Yuming 4 ; Cai, Yonglin 4 ; Chang, Ellen T 5 ; Zhang, Zhe 6 ; Huang, Guangwu 6 ; Su‐Mei Cao 1 ; Liu, Qing 1 ; Lin, Feng 1 ; Sun, Ying 7   VIAFID ORCID Logo  ; Maria Li Lung 8 ; Hans‐Olov Adami 9 ; Ye, Weimin 10 ; Tai‐Hing Lam 11 ; Wei‐Hua Jia 12   VIAFID ORCID Logo 

1  State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat‐sen University Cancer Center, Guangzhou, Guangdong, P. R. China 
2  School of Public Health, The University of Hong Kong, Hong Kong S.A.R., P. R. China; Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., P. R. China; Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 
3  School of Public Health, Sun Yat‐sen University, Guangzhou, Guangdong, P. R. China 
4  Wuzhou Red Cross Hospital, Wuzhou, Guangxi, P. R. China; Wuzhou Cancer Center, Wuzhou, Guangxi, P. R. China 
5  Center for Health Sciences, Exponent, Inc., Menlo Park, CA, 94025, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA 
6  Department of Otolaryngology‐Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P. R. China 
7  Department of Radiation Oncology, Sun Yat‐sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong, P. R. China 
8  Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., P. R. China; Department of Clinical Oncology, The University of Hong Kong, Hong Kong S.A.R., P. R. China 
9  Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, Norway; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 
10  Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Epidemiology and Health Statistics & Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian, P. R. China 
11  School of Public Health, The University of Hong Kong, Hong Kong S.A.R., P. R. China; Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., P. R. China 
12  State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat‐sen University Cancer Center, Guangzhou, Guangdong, P. R. China; School of Public Health, Sun Yat‐sen University, Guangzhou, Guangdong, P. R. China 
Pages
887-891
Section
LETTERS TO THE EDITOR
Publication year
2022
Publication date
Sep 2022
Publisher
John Wiley & Sons, Inc.
e-ISSN
2523-3548
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1002/cac2.12317
ProQuest document ID
2711550556
Copyright
© 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.